Zhang Wenyuan, Peng Dan, Cheng Shiqi, Ni Rui, Yang Meiyang, Cai Yongqing, Chen Jianhong, Liu Fang, Liu Yao
Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
Bioengineering (Basel). 2025 Feb 19;12(2):205. doi: 10.3390/bioengineering12020205.
Myocardial infarction (MI) is a cardiovascular disease (CVD) with high morbidity and mortality worldwide, which is a serious threat to human life and health. Inflammatory and immune responses are initiated immediately after MI, and unbalanced inflammation post-MI can lead to cardiac dysfunction, scarring, and ventricular remodeling, emphasizing the critical need for an effective inflammation-regulating treatment. With the development of novel therapies, the drug delivery system specific to inflammatory cells offers significant potential. In this review, we introduce immune cells and fibroblasts involved in the development of MI and summarize the newly developed delivery systems related to the use of injectable hydrogels, cardiac patches, nanoparticles, and extracellular vesicles (EVs). Finally, we highlight the recent trends in the use of inflammatory cell-targeting drug delivery systems involving different strategies that facilitate the effective treatment of MI.
心肌梗死（MI）是一种在全球范围内发病率和死亡率都很高的心血管疾病（CVD），对人类生命和健康构成严重威胁。心肌梗死后立即启动炎症和免疫反应，心肌梗死后炎症失衡可导致心脏功能障碍、瘢痕形成和心室重塑，这凸显了有效炎症调节治疗的迫切需求。随着新型疗法的发展，针对炎症细胞的药物递送系统具有巨大潜力。在本综述中，我们介绍了参与心肌梗死发展的免疫细胞和成纤维细胞，并总结了与可注射水凝胶、心脏贴片、纳米颗粒和细胞外囊泡（EVs）相关的新开发递送系统。最后，我们强调了使用炎症细胞靶向药物递送系统的最新趋势，这些系统涉及不同策略，有助于有效治疗心肌梗死。
